Drug Trial Radar · NCT03740737
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
579
Actual
Start
Oct 26, 2018
Primary completion
Nov 11, 2020
Study completion Nov 11, 2020
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 34 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial investigates the effects of FE 999049 compared to placebo.
Conditions
- Infertility
Interventions
Follitropin deltaDrug
FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed.
PlaceboOther
Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COSTime frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Fertility Treatment Center
Tempe, Arizona
HRC Fertility
Encino, California
Center for Advanced Reproductive Services PC
Farmington, Connecticut
Reproductive Associates of Delaware
Newark, Delaware
Women's Medical Research Group, LLC
Clearwater, Florida
Center for Reproductive Medicine
Winter Park, Florida
Fertility Institute of Hawaii, INC
Honolulu, Hawaii
Fertility Centers of Illinois (RH)
Chicago, Illinois
InVia Fertility
Hoffman Estates, Illinois
Boston IVF
Waltham, Massachusetts
Mayo Clinic
Rochester, Minnesota
Reproductive Endocrinology Associates of Charlotte (REACH) S. Corporation
Charlotte, North Carolina
Carolina Conceptions
Raleigh, North Carolina
Institute for Reproductive Health
Cincinnati, Ohio
Abington Reproductive Medicine
Abington, Pennsylvania
Main Line Fertility Center
Bryn Mawr, Pennsylvania
Fertility Associates of Memphis, PLLC
Memphis, Tennessee
Center for Assisted Reproduction
Bedford, Texas
Houston Fertility Institute
Houston, Texas
Center of Reproductive Medicine
Webster, Texas
Utah Fertility Center
Pleasant Grove, Utah
Eastern Virginia Medical School | EVMS Obstetrics & Gynecology
Norfolk, Virginia
Seattle Reproductive Medicine WA
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.